. 2017 Sep 18;8(46):81697–81708. doi: 10.18632/oncotarget.21009

Table 2. The contrast of the clinicopathological characteristics between T-LGLL after transplantation and de novo T-LGLL.

	Median age (years)	Male:Female	Clinical features	Phenotype	Treatment	STAT3 mutations	Associated virus
de novo T-LGLL	60	1:1	Asymptomatic;symptomatic with cytopenia or autoimmune conditions(RA, PRCA, ITP, etc.)	CD3⁺CD4^+/− CD8⁺CD16⁺CD56⁻CD57⁺TCRαβ⁺ (10% are TCRγδ⁺)	Observation or immunosuppressive regimen	Yes	HTLV
T-LGLL after transplantation	50 [11] 48.5 [12]	4:3 [11] 11:3 [12]	Similar to de novo T-LGLL, less prevalent autoimmune disease, and emergence after transplantation	CD3⁺CD4⁻CD8⁺CD16⁺CD26⁻CD28⁻CD56⁻CD57⁺TCRαβ⁺TCRγδ⁻	Observation or reduced immunosuppression	No	CMV

Abbreviations: RA, rheumatoid arthritis; PRCA, pure red cell aplasia; ITP, immune thrombocytopenia; HTLV, human T-cell leukemia/lymphoma virus; CMV, cytomegalovirus.